XILIO THERAPEUTICS IN

Xilio Therapeutics Appoints Stacey Davis as Chief Business Officer

17 May 2022 07:30:00 By Nasdaq GlobeNewswire

Xilio Therapeutics Reports Pipeline and Business Highlights and First Quarter 2022 Financial Results

12 May 2022 07:30:00 By Nasdaq GlobeNewswire

Xilio Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference

07 Apr 2022 06:30:00 By Nasdaq GlobeNewswire

Xilio Therapeutics Reports Pipeline and Business Progress and Fourth Quarter and Full Year 2021 Financial Results

01 Mar 2022 06:30:00 By Nasdaq GlobeNewswire

Xilio Therapeutics to Participate in the Cowen 42nd Annual Healthcare Conference

28 Feb 2022 06:30:00 By Nasdaq GlobeNewswire

Xilio Therapeutics to Participate in the Guggenheim 4th Annual Oncology Day

03 Feb 2022 06:30:00 By Nasdaq GlobeNewswire

Xilio Therapeutics Announces Initiation of Patient Dosing in Phase 1/2 Clinical Trial of XTX202 for the Treatment of Patients with Solid Tumors

20 Jan 2022 07:30:00 By Nasdaq GlobeNewswire

Xilio Therapeutics Appoints Yuan Xu, Ph.D., to its Board of Directors

06 Jan 2022 07:30:00 By Nasdaq GlobeNewswire

Xilio Therapeutics Reports Pipeline and Business Progress and Third Quarter 2021 Financial Results

02 Dec 2021 07:30:00 By Nasdaq GlobeNewswire

Xilio Therapeutics Announces Preclinical Data Demonstrating Anti-Tumor Activity and Tolerability of XTX301, a Tumor-Selective IL-12, at Society for Immunotherapy in Cancer Annual Meeting

12 Nov 2021 07:00:03 By Nasdaq GlobeNewswire

Xilio Therapeutics Announces Closing of Initial Public Offering

26 Oct 2021 16:05:00 By Nasdaq GlobeNewswire